Aequus Pharmaceuticals Inc. (AQSZF)
AQSZF Stock Price Chart
Explore Aequus Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze AQSZF price movements and trends.
AQSZF Company Profile
Discover essential business fundamentals and corporate details for Aequus Pharmaceuticals Inc. (AQSZF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
16 Jun 2015
Employees
12.00
Website
https://www.aequuspharma.caCEO
Douglas Glen Janzen
Description
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
AQSZF Financial Timeline
Browse a chronological timeline of Aequus Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 19 May 2026
Upcoming earnings on 19 May 2026
Upcoming earnings on 6 Nov 2025
Earnings released on 27 Aug 2025
Earnings released on 21 May 2025
EPS came in at -$0.00 , while revenue for the quarter reached $159.08K .
Earnings released on 24 Apr 2025
EPS came in at -$0.00 , while revenue for the quarter reached $154.23K .
Earnings released on 8 Nov 2024
EPS came in at -$0.00 , while revenue for the quarter reached $109.29K .
Earnings released on 29 Aug 2024
EPS came in at -$0.00 , while revenue for the quarter reached $118.06K .
Earnings released on 9 May 2024
EPS came in at -$0.00 , while revenue for the quarter reached $38.70K .
Earnings released on 29 Apr 2024
EPS came in at -$0.00 , while revenue for the quarter reached $38.31K .
Earnings released on 29 Nov 2023
EPS came in at -$0.00 , while revenue for the quarter reached $9.86K .
Earnings released on 30 Aug 2023
EPS came in at -$0.00 , while revenue for the quarter reached $74.29K .
Earnings released on 31 May 2023
EPS came in at -$0.00 , while revenue for the quarter reached $68.18K .
Earnings released on 2 May 2023
EPS came in at -$0.01 , while revenue for the quarter reached $285.50K .
Earnings released on 30 Nov 2022
EPS came in at -$0.00 , while revenue for the quarter reached $254.06K .
Earnings released on 29 Aug 2022
EPS came in at -$0.00 , while revenue for the quarter reached $269.00K .
Earnings released on 17 Jun 2022
EPS came in at -$0.00 , while revenue for the quarter reached $673.90K .
Earnings released on 31 Mar 2022
EPS came in at -$0.01 , while revenue for the quarter reached $241.78K .
Earnings released on 3 Nov 2021
EPS came in at -$0.00 , while revenue for the quarter reached $525.62K .
Earnings released on 30 Sept 2021
EPS came in at -$0.00 , while revenue for the quarter reached $561.65K .
Earnings released on 31 Mar 2021
EPS came in at -$0.00 , while revenue for the quarter reached $391.30K .
Earnings released on 31 Dec 2020
EPS came in at -$0.00 , while revenue for the quarter reached $666.78K .
Earnings released on 30 Sept 2020
EPS came in at -$0.00 , while revenue for the quarter reached $464.93K .
AQSZF Stock Performance
Access detailed AQSZF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.